

Pierre-Yves Dietrich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5925072/publications.pdf>

Version: 2024-02-01

40
papers

1,418
citations

430874

18
h-index

361022

35
g-index

41
all docs

41
docs citations

41
times ranked

2683
citing authors

#	ARTICLE	IF	CITATIONS
1	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66.	10.2	203
2	Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer. <i>IScience</i> , 2022, 25, 103699.	4.1	5
3	Digital patient-reported outcomes and serological response to SARS-COV-2 vaccines in patients with cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13606-e13606.	1.6	0
4	DESC-1, a prospective study on epidemiologic factors influencing general population to engage with liquid biopsy based cancer screening.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13630-e13630.	1.6	0
5	Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread. <i>Neurology: Genetics</i> , 2021, 7, e561.	1.9	1
6	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. <i>Cancer Treatment Reviews</i> , 2021, 97, 102204.	7.7	24
7	Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. <i>Communications Biology</i> , 2021, 4, 718.	4.4	14
8	Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. <i>Science Immunology</i> , 2021, 6, .	11.9	47
9	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. <i>Cancer Cell</i> , 2021, 39, 1091-1098.e2.	16.8	199
10	Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). <i>JCI Insight</i> , 2021, 6, .	5.0	7
11	Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. <i>OncImmunity</i> , 2020, 9, 1779990.	4.6	28
12	An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin. <i>Biology</i> , 2020, 9, 264.	2.8	7
13	Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. <i>Cancers</i> , 2020, 12, 1423.	3.7	25
14	Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1783.	2.6	9
15	Modeling Poliovirus Infection Using Human Engineered Neural Tissue Enriched With Motor Neuron Derived From Embryonic Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 593106.	3.7	0
16	Peptides as cancer vaccines. <i>Current Opinion in Pharmacology</i> , 2019, 47, 20-26.	3.5	75
17	Phase I/II trial testing safety and immunogenicity of the multi-peptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. <i>Neuro-Oncology</i> , 2019, 21, 923-933.	1.2	89
18	Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. <i>OncImmunity</i> , 2018, 7, e1391972.	4.6	42

#	ARTICLE	IF	CITATIONS
19	CAR T-Cell Therapies in Glioblastoma: A First Look. <i>Clinical Cancer Research</i> , 2018, 24, 535-540.	7.0	103
20	Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy. <i>Nutrition and Cancer</i> , 2018, 70, 1069-1074.	2.0	0
21	Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. <i>Oncolmunology</i> , 2018, 7, e1501137.	4.6	120
22	Diagnosis and treatment of follicular lymphoma: an update. <i>Swiss Medical Weekly</i> , 2018, 148, w14635.	1.6	12
23	Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. <i>Swiss Medical Weekly</i> , 2018, 148, w14596.	1.6	6
24	Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer. <i>Digestive and Liver Disease</i> , 2017, 49, 1262-1266.	0.9	2
25	Identification of a novel population of highly cytotoxic CD8 ⁺ T lymphocytes. <i>EMBO Reports</i> , 2017, 18, 1545-1558.	4.5	22
26	Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. <i>Cancer Cell</i> , 2017, 32, 856-868.e5.	16.8	121
27	First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. <i>Oncolmunology</i> , 2017, 6, e1338235.	4.6	52
28	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. <i>Frontiers in Oncology</i> , 2016, 6, 256.	2.8	39
29	Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. <i>PLoS ONE</i> , 2016, 11, e0162105.	2.5	17
30	Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. <i>Molecular Therapy</i> , 2016, 24, 1675-1685.	8.2	29
31	Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis. <i>Cancer Medicine</i> , 2016, 5, 1098-1107.	2.8	6
32	Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing?. <i>CNS Oncology</i> , 2016, 5, 199-201.	3.0	1
33	Cell-penetrating peptides—the Swiss Army knife of cancer vaccines. <i>Oncolmunology</i> , 2016, 5, e1095435.	4.6	5
34	Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer. <i>Anticancer Research</i> , 2016, 36, 2359-64.	1.1	7
35	Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review. <i>CNS Oncology</i> , 2015, 4, 387-392.	3.0	28
36	Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4 ⁺ and CD8 ⁺ T Cell-Mediated Antitumor Immunity. <i>Cancer Research</i> , 2015, 75, 3020-3031.	0.9	50

#	ARTICLE	IF	CITATIONS
37	Immunotherapy for Glioma: From Illusion to Realistic Prospects?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 51-59.	3.8	5
38	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	9
39	Outcome of patients with nonmetastatic, muscle-invasive bladder cancer (MIBC), not undergoing cystectomy, after treatment with non-cisplatin-based chemotherapy and/or radiotherapy: A retrospective analysis.. Journal of Clinical Oncology, 2013, 31, e15619-e15619.	1.6	0
40	Survivin in Brain Tumors: An Attractive Target for Immunotherapy. Journal of Neuro-Oncology, 2003, 64, 71-76.	2.9	9